Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders

Trends in Pharmacological Sciences

Volumn 30, Issue 11, 2009, Pages 570-580

  Fiorucci, Stefano ^a   Mencarelli, Andrea ^a   Palladino, Giuseppe ^a   Cipriani, Sabrina ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; 6ALPHA ETHYL CHENODEOXYCHOLIC ACID; AGENTS AFFECTING LIPID METABOLISM; AGENTS AFFECTING METABOLISM; ALOGLIPTIN; BILE ACID; CHENODEOXYCHOLIC ACID; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; FARNESOID X RECEPTOR; FERAXAMINE; FXR 450; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR TGR5; GLITAZONE DERIVATIVE; HORMONE RECEPTOR AFFECTING AGENT; HORMONE RECEPTOR STIMULATING AGENT; INCRETIN; LIRAGLUTIDE; MFA 1; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; OLEANOLIC ACID; PREGNANE X RECEPTOR; SAXAGLIPTIN; SITAGLIPTIN; THYROID HORMONE; UNCLASSIFIED DRUG; VILDAGLIPTIN; VITAMIN D RECEPTOR; WAY 362450; XL 335;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL; DISORDERS OF CARBOHYDRATE METABOLISM; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ENERGY EXPENDITURE; FAT NECROSIS; FATTY LIVER; GLUCOSE HOMEOSTASIS; HEART RATE; HEPATITIS; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; LIPOPROTEIN METABOLISM; LIVER FIBROSIS; NITROGEN URINE LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; WEIGHT GAIN;

ANIMALS; BILE ACIDS AND SALTS; BLOOD GLUCOSE; DRUG DELIVERY SYSTEMS; DYSLIPIDEMIAS; GLUCOSE METABOLISM DISORDERS; HOMEOSTASIS; HUMANS; LIGANDS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, G-PROTEIN-COUPLED;

EID: 70350292362     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2009.08.001     Document Type: Review

References (87)

1. Reaven G.M. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
2. Lavie C.J. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J. Am. Coll. Cardiol. 53 (2009) 1925-1932
3. Russell D.W. The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 72 (2003) 137-174
4. Maruyama T., et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem. Biophys. Res. Commun. 298 (2002) 714-719
5. Moore D.D., et al. International Union of Pharmacology. LXII. The NR1H and NR1I receptors: constitutive androstane receptor, pregnene X receptor, farnesoid X receptor α, farnesoid X receptor β, liver X receptor α, liver X receptor β, and vitamin D receptor. Pharmacol. Rev. 58 (2006) 742-759
6. Kawamata Y., et al. A G protein-coupled receptor responsive to bile acids. J. Biol. Chem. 278 (2003) 9435-9440
7. Sato H., et al. Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure, activity relationships, and molecular modeling studies. J. Med. Chem. 51 (2008) 1831-1841
8. Pellicciari R., et al. Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5. J. Med. Chem. 50 (2007) 4265-4268
9. Nguyen A., et al. Bile acids and signal transduction: role in glucose homeostasis. Cell Signal 20 (2008) 2180-2197
10. Thomas C., et al. Targeting bile-acid signalling for metabolic diseases. Nat. Rev. Drug Discov. 7 (2008) 678-693
11. Watanabe M., et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439 (2006) 484-489
12. Maruyama T., et al. Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice. J. Endocrinol. 191 (2006) 197-205
13. Katsuma S., et al. Bile acids promote glucagon like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem. Biophys. Res. Commun. 329 (2005) 386-390
14. Vassileva G., et al. Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation. Biochem. J. 398 (2006) 423-430
15. Baggio L.L., and Druker D.J. Biology of incretins: GLP1 and GIP. Gastroenterology 132 (2007) 2131-2157
16. Sato H., et al. Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea. Biochem. Biophys. Res. Commun. 362 (2007) 793-798
17. Keitel V., et al. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology 45 (2007) 695-704
18. Keitel V., et al. Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem. Biophys. Res. Commun. 372 (2008) 78-84
19. Yang J.I., et al. Bile acid-induced TGR5-dependent c-Jun-N terminal kinase activation leads to enhanced caspase 8 activation in hepatocytes. Biochem. Biophys. Res. Commun. 361 (2007) 156-161
20. Lefebvre P., et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 89 (2009) 147-191
21. Sinal C.J., et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102 (2000) 731-744
22. Maloney P.R., et al. Identification of a chemical tool for the orphan nuclear receptor FXR. J. Med. Chem. 43 (2000) 2971-2974
23. Pellicciari R., et al. 6α-Ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem. 45 (2002) 3569-3572
24. Downes M., et al. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol. Cell 11 (2003) 1079-1092
25. Pellicciari R., et al. Farnesoid X receptor: from structure to potential clinical applications. J. Med. Chem. 48 (2005) 5383-5403
26. Fiorucci S., et al. Targeting FXR for liver and metabolic indications. Trends Mol. Med. 13 (2007) 298-309
27. Otte K., et al. Identification of farnesoid X receptor β as a novel mammalian nuclear receptor sensing lanosterol. Mol. Cell. Biol. 23 (2003) 864-872
28. Marzolini C., et al. A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. Mol. Endocrinol. 21 (2007) 1769-1780
29. Van Mil S.A., et al. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology 133 (2007) 507-516
30. Lee F.L., et al. FXR, a multipurpose nuclear receptor. Trends Biochem. Sci. 31 (2006) 572-580
31. Goodwin B., et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell 6 (2000) 517-526
32. Lu T.T., et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell 6 (2000) 507-515
33. Brendel C., et al. The small heterodimer partner interacts with the liver X receptor α and represses its transcriptional activity. Mol. Endocrinol. 16 (2002) 2065-2076
34. Stedman C., et al. Feed-forward regulation of bile acid detoxification by CYP3A4: studies in humanized transgenic mice. J. Biol. Chem. 279 (2004) 11336-11343
35. Kerr T.A., et al. Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis. Dev. Cell 2 (2002) 713-720
36. Fiorucci S., et al. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J. Pharmacol. Exp. Ther. 313 (2005) 604-612
37. Denson L.A., et al. The orphan nuclear receptor, Shp, mediates bile acid-induced inhibition of the rat bile acid transporter. Gastroenterology 121 (2001) 140-147
38. Yu X.Q., et al. Multidrug resistance associated proteins as determining factors of pharmacokinetics and pharmacodynamics of drugs. Curr. Drug Metab. 8 (2007) 787-802
39. Ballatori N., et al. OSTα-OSTβ: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology 42 (2005) 1270-1279
40. Zollner G., et al. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol. Pharm. 3 (2006) 231-250
41. Yu C., et al. Independent repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile acids. J. Biol. Chem. 280 (2005) 17707-17714
42. Inagaki T., et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2 (2005) 217-225
43. Shin D.J., and Osborne T.F. FGF15/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action. J. Biol. Chem. 284 (2009) 11110-11120
44. Chiang, J.Y. (2009) Bile acids: regulation of synthesis. J. Lipid Res. (in press) DOI: 10.1194/jlr.R900010-JLR200
45. Jung D., et al. FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption. J. Lipid Res. 48 (2007) 2693-2700
46. Kim I., et al. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J. Lipid Res. 48 (2007) 2664-2672
47. Fiorucci S., and Baldelli F. Farnesoid X receptor agonists in biliary tract disease. Curr. Opin. Gastroenterol. 25 (2009) 252-259
48. Kast H.R., et al. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol. Endocrinol. 15 (2001) 1720-1728
49. Lambert G., et al. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J. Biol. Chem. 278 (2003) 2563-2570
50. Hanniman E.A., et al. Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J. Lipid Res. 46 (2005) 2595-2604
51. Watanabe M., et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J. Clin. Invest. 113 (2004) 1408-1418
52. Mencarelli A., et al. Antiatherosclerotic effect of farnesoid X receptor. Am. J. Physiol. Heart Circ. Physiol. 296 (2009) H272-281
53. -/- mice. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 2316-2321
54. -/- mice. J Lipid Res. 50 (2009) 1090-1100
55. Zhang Y., et al. Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev. 18 (2004) 157-169
56. Claudel T., et al. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J. Clin. Invest. 109 (2002) 961-971
57. Farrell G.C. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43 (2006) S99-S112
58. Belfort R., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355 (2006) 2297-2307
59. Zhang, S. et al. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J. Hepatol. 51, 380-388
60. Cipriani S., et al. FXR activation reverses insulin resistance and protects against NASH development. Gastroenterology 136 Suppl. 1 (2009) M1735
61. Stayrook K.R., et al. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 146 (2005) 984-991
62. Thomas C., et al. Bile acids and the membrane bile acid receptor TGR5 - connecting nutrition and metabolism. Thyroid 18 (2008) 167-174
63. Yamagata K., et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J. Biol. Chem. 279 (2004) 23158-23165
64. Duran-Sandoval D., et al. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J. Biol. Chem. 280 (2005) 29971-29979
65. Duran-Sandoval D., et al. Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 53 (2004) 890-898
66. Zhang Y., et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 1006-1011
67. Ma K., et al. Farnesoid X receptor is essential for normal glucose homeostasis. J. Clin Invest. 116 (2006) 1102-1109
68. Cariou B., et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J. Biol. Chem. 281 (2006) 11039-11049
69. Macchiarulo A., et al. Molecular field analysis and 3D-quantitative structure-activity relationship study (MFA 3D-QSAR) unveil novel features of bile acid recognition at TGR5. J. Chem. Inf. Model. 48 (2008) 1792-1801
70. Tiwari A., and Maiti P. TGR5: an emerging bile acid G-protein-coupled receptor target for the potential treatment of metabolic disorders. Drug. Disc. Today 14 (2009) 9-10
71. Pinkerton, A.B. et al. Kalypsys, Inc. Qiunazoline modulators of TGR5, WO2008067219A2
72. Pinkerton, A.B. et al. Kalypsys, Inc. Heterocyclic modulators of TGR5, WO2008067222A1
73. Pinkerton, A.B. et al. Kalypsys, Inc. Heterocyclic modulators of TGR5 for treatment of disease, WO2008097976A1
74. Tan K.P., et al. Activation of nuclear factor (erythroid-2 like) factor 2 by toxic bile acids provokes adaptive defense responses to enhance cell survival at the emergence of oxidative stress. Mol. Pharmacol. 72 (2007) 1380-1390
75. Kirsi A., et al. Functional brown adipose tissue in healthy adults. New Engl. J. Med. 360 (2009) 1518-1525
76. Mi L.Z., et al. Structural basis for bile acid binding and activation of the nuclear receptor FXR. Mol. Cell 11 (2003) 1093-1100
77. Akawabi-Ameyaw A., et al. Conformationally constrained farnesoid X receptor (FXR) agonists: naphthoic acid-based analogs of GW 4064 Bioorg. Med. Chem. Lett. 18 (2008) 4339-4343
78. Zhang T., et al. 3D-QSAR studies with the aid of molecular docking for a series of non-steroidal FXR agonists. Bioorg. Med. Chem. Lett. 17 (2007) 2156-2160
79. Suzuki T., et al. The novel compounds that activate farnesoid X receptor: the diversity of their effects on gene expression. J. Pharmacol. Sci. 107 (2008) 285-294
80. Soisson S.M., et al. Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 5337-5342
81. Houck K.A., et al. T0901317 is a dual LXR/FXR agonist. Mol. Genet. Metab. 83 (2004) 184-187
82. Evans M.J., et al. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am. J. Physiol. Gastrointest. Liver Physiol. 296 (2009) G543-552
83. Dussault I., et al. Identification of gene-selective modulators of the bile acid receptor FXR. J. Biol. Chem. 278 (2003) 7027-7033
84. Urizar N.L., et al. A natural product that lowers cholesterol as an antagonist ligand for the FXR. Science 296 (2002) 1703-1706
85. Burris T.P., et al. The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand. Mol. Pharmacol. 67 (2005) 948-954
86. Cui J., et al. Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J. Biol. Chem. 278 (2003) 10214-10220
87. Szapary P.O., et al. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. J. Am. Med. Assoc. 290 (2003) 765-772